利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

446 条记录 (耗时 0.039 秒)

    Pharmaceutical composition
    1.
    发明授权
    Pharmaceutical composition 失效
    药物组成

    公开(公告)号：US4983605A

    公开(公告)日：1991-01-08

    申请号：US110284

    申请日：1987-10-20

    申请人： Nobuo Kondo ,  Masahiro Kikuchi ,  Tsunetaka Nakajima ,  Masahiro Watanabe ,  Kazumasa Yokoyama ,  Takahiro Haga ,  Nobutoshi Yamada ,  Hideo Sugi ,  Toru Koyanagi

    发明人： Nobuo Kondo ,  Masahiro Kikuchi ,  Tsunetaka Nakajima ,  Masahiro Watanabe ,  Kazumasa Yokoyama ,  Takahiro Haga ,  Nobutoshi Yamada ,  Hideo Sugi ,  Toru Koyanagi

    IPC分类号： A61K9/14 ,  A61K9/19 ,  A61K31/44 ,  A61K31/50 ,  A61K31/505 ,  A61K47/14 ,  A61K47/26

    CPC分类号： A61K31/505 ,  A61K31/44 ,  A61K31/50 ,  A61K9/145 ,  A61K9/146 ,  A61K9/19 ,  A61K47/14 ,  A61K47/26 ,  Y10S514/961 ,  Y10S514/964

    摘要： A pharmaceutical composition comprising a benzoyl urea compound (A) selected from the group consisting of a benzoyl urea compound (I) having the formula: ##STR1## wherein X is a halogen atom, a nitro group or a trifluoromethyl group, provided that when Y is a nitro group, X is a halogen atom or a nitro group, Y is a hydrogen atom, a halogen atom, a nitro group or a trifluoromethyl group, Z.sub.1 is a halogen atom or a trifluoromethyl group, Z.sub.2 is a hydrogen atom or a halogen atom, and A is a .dbd.CH-- group or a nitrogen atom, and a benzoyl urea compound (II) having the formula: ##STR2## wherein each of X.sub.1 and X.sub.2 is a hydrogen atom, a halogen atom or a nitro group, provided that when Y is a nitro group, X.sub.1 is a hydrogen atom, Y is a hydrogen atom, a halogen atom, a nitro group or a trifluoromethyl group, and Z is a hydrogen atom, a halogen atom or a trifluoromethyl group, as an active ingredient; a nonionic surfactant as a dispersant; and at least one member selected from the group consisting of a saccharide, a saccharide alcohol, silicic anhydride and a nonionic surfactant, as a disintegrator.

    摘要翻译： 提供一种药物组合物，其包含选自具有下式的苯甲酰脲化合物（I）的苯甲酰脲化合物（A）：其中X为卤素原子，硝基或三氟甲基，其提供 当Y为硝基时，X为卤原子或硝基，Y为氢原子，卤原子，硝基或三氟甲基，Z1为卤原子或三氟甲基，Z2为氢 原子或卤素原子，A为= CH-基或氮原子，和具有下式的苯甲酰脲化合物（II）：其中X1和X2各自为氢原子，卤素 原子或硝基，条件是当Y为硝基时，X 1为氢原子，Y为氢原子，卤素原子，硝基或三氟甲基，Z为氢原子，卤素原子或 三氟甲基作为活性成分; 作为分散剂的非离子表面活性剂; 和选自糖，糖醇，硅酸酐和非离子表面活性剂的至少一种作为崩解剂。

    Peptide derivatives
    10.
    发明授权
    Peptide derivatives 失效
    肽衍生物

    公开(公告)号：US4775743A

    公开(公告)日：1988-10-04

    申请号：US905815

    申请日：1986-09-10

    申请人： Tsutomu Mimura ,  Yasuhiro Kohama ,  Chikara Fukaya ,  Masahiro Watanabe ,  Kazumasa Yokoyama

    发明人： Tsutomu Mimura ,  Yasuhiro Kohama ,  Chikara Fukaya ,  Masahiro Watanabe ,  Kazumasa Yokoyama

    IPC分类号： A61K38/00 ,  A61P7/02 ,  A61P9/06 ,  C07K5/06 ,  C07K7/06 ,  C07K7/18

    CPC分类号： C07K7/06 ,  C07K5/06026 ,  C07K7/18 ,  A61K38/00 ,  Y10S514/821

    摘要： New peptide derivatives represented by the following general formulaR.sub.1 -Pro-Hyp-R.sub.2wherein R.sub.1 is a hydrophobic radical, R.sub.2 is a hydrophilic radical, Pro is prolyl and Hyp is hydroxyprolyl show more powerful inhibitory action against platelet agglutination than conventional drugs and have potential use as anti-agglutination agent. The peptide derivative can be prepared by condensing a peptide containing a hydrophobic radical with a carboxylic acid containing a hydrophilic radical. The peptide derivative can be used in the form of parenteral injections, tablets, capsules or powder, the typical daily dose being in the range from 1 mg to 500 mg for adults.

    摘要翻译： 由以下通式R1-Pro-Hyp-R2表示的新肽衍生物，其中R1是疏水基团，R2是亲水基团，Pro是脯氨酰基，Hyp是羟基脯氨酸，比常规药物显示更强大的抗血小板凝集抑制作用，并具有潜力 用作抗凝集剂。 肽衍生物可以通过将含有疏水基团的肽与含有亲水基团的羧酸缩合而制备。 肽衍生物可以以肠胃外注射，片剂，胶囊或粉末的形式使用，成人的典型日剂量范围为1mg至500mg。